More than 40 years ago, the so-called gate control theory of pain proposed by Ronald Melzack and Patrick Wall [1] has postulated that inhibitory neurons in the spinal cord dorsal horn would control the transmission of nociceptive ("pain") signals coming from the periphery through the spinal cord to higher brain areas where pain becomes conscious. Since these early days, the nature of this inhibitory control has been unraveled and γ-aminobutyric acid (GABA) and glycine have been identified as the two fast inhibitory neurotransmitters in the spinal dorsal horn. Subsequently, it was proven that pharmacological blockade of GABA or glycine receptors in the spinal dorsal horn provokes pain sensation in animals as well as in humans [2, 3] . More recently, several groups could also demonstrate that a reduction in GABAergic and glycinergic neurotransmission occurs naturally in the course of inflammatory and neuropathic pain [4] . Accordingly, restoring the function of inhibitory neurotransmission in the spinal dorsal horn should be a rational approach to the treatment of chronic pain conditions. However, attempts to translate the gate control theory into novel pharmacotherapies of pain have failed miserably. This is particularly surprising because GABA A receptors are among the most successfully exploited drug targets. Drugs acting at GABA A receptors include the benzodiazepine site agonists ("benzodiazepines") which facilitate the action of GABA at GABA A receptors and which are widely used clinically for their sleep promoting, anxiolytic, and anticonvulsive effects. However, although anecdotal evidence exists for a painrelieving effect in certain groups of patients, the vast majority of reports indicate that benzodiazepines do not exert a clear analgesic effect in patients or in human experimental pain models [5] . This is again surprising for several reasons. Benzodiazepine-sensitive GABA A receptors are found in the spinal terminals of primary nociceptors as well as at other sites in the pain pathway including neurons in the superficial layers of the spinal dorsal horn [6] , a pivotal structure for the processing of pain signals. Local spinal injection of benzodiazepines (mainly diazepam or its short acting and rather hydrophilic derivative midazolam) is antinociceptive both in animal experiments [7] [8] [9] and in human patients [10, 11] . Part of this discrepancy is probably due to the fact that experimental studies hardly discriminated between acute analgesic (antinociceptive) effects (e.g. [12] ) and a reversal of pathologically increased pain sensitivity (antihyperalgesia). In fact, a recent study showed that intrathecal injection of diazepam in mice normalized pain thresholds in mice suffering from increased pain sensitivity due to peripheral inflammation or nerve damage but had no effect on acute nociceptive pain [13] . It is however still surprising that classical benzodiazepines are not analgesic in patients with chronic pain who usually also show pronounced hyperalgesia.
What are possible explanations for this apparent discrepancy? Animal studies on pain largely rely on the assessment of nociceptive withdrawal reflexes upon exposure of a paw or the tail to a painful stimulus (heat, cold, or mechanical stress) as a measure of changes in pain sensitivity. Positive results from animal studies could hence be confounded by sedation, muscle relaxation, or reversal of anxiety-induced hyperalgesia. It is also possible that pain relief might occur only at doses sufficiently high to provoke at the same time strong sedation making it extremely difficult to distinguish analgesia from sedation. Alternatively, if benzodiazepines were in fact analgesic after spinal but not after systemic application, pronociceptive effects at supraspinal sites might antagonize spinal antihyperalgesic actions. Such pronociceptive effects have indeed been reported after intracerebroventricular injection of midazolam [8] .
Fortunately, benzodiazepines exert their effects not through a single but through at least four different subtypes of GABA A receptors enabling the pharmacological separation of different benzodiazepine effects. GABA A receptors are heteropentameric chloride channels assembled from a repertoire of α, β, γ, δ, ɛ, θ, π, and ρ subunits [14] . Benzodiazepine-sensitive GABA A receptors, which make up the majority of GABA A receptors in the nervous system including the spinal cord, are composed of two α (α1, α2, α3 or α5) subunits, two β subunits, and one γ2 subunit. All benzodiazepine-sensitive GABA A receptors contain a conserved histidine residue in their extracellular N-terminal domain, while the benzodiazepine-insensitive subunits (α4 and α6) carry an arginine at the same site [15] . Mutation of this histidine residue renders GABA A receptor α subunits diazepam-insensitive. The generation of so-called point mutated or knock-in mice for all four benzodiazepinesensitive GABA A receptor α subunits (α1(H101R), α2 (H101R), α3(H126R), and α5(H105R)) by Rudolph and Mohler [16] allowed to attribute the different in vivo actions of benzodiazepines to molecularly defined GABA A receptor subtypes (Fig. 1 ). Using these mice, it has become possible to attribute the sedative effects of diazepam to GABA A receptors containing the α1 subunit [17] , while the anxiolytic effects were mediated through the α2 GABA A receptors [18] . Using these mice in models of inflammatory and neuropathic pain, we were recently able to demonstrate that the spinal antihyperalgesic effects of diazepam were mediated mainly through GABA A receptors containing α2 subunit [13] . α1 subunits did not contribute significantly in any of the pain models tested, while α3 and α5 subunits showed some contribution depending on the pain model used and the type of stimulus (heat, cold, or mechanical stress) employed. Importantly, intrathecal treatment with diazepam did not cause sedation and did not affect responses of the non-inflamed or non-injured paw indicating that sedation or muscle relaxation were not major confounding factors. Importantly, these results also indicated that the GABA A receptor subtypes responsible for benzodiazepine-induced antihyperalgesia were different from those that mediate sedation. This allowed the investigation of possible antihyperalgesic actions of sys- Fig. 1 Contribution of different GABA A receptor subtypes to benzodiazepine-mediated spinal antihyperalgesia (A) and in comparison to other desired or undesired effects of classical benzodiazepines (B). Data modified from references [13] , [17] , [18] , [28] , and [29] temic benzodiazepines in the absence of sedation either through the analysis of mice carrying mutated α1 subunits or through the use of so-called α1-sparing or non-sedative benzodiazepine site ligands.
Both approaches yielded similarly positive results. A recent study investigated the possible antihyperalgesic effect of systemic diazepam in mice carrying point mutated α1 subunits (α1(H101R)) [19] . These mice displayed antihyperalgesia in response to systemic diazepam virtually identical to that seen in the corresponding wild-type mice but without any signs of sedation. The same study also analyzed mice which carried in addition to α1(H101R) a second benzodiazepine-insensitive α subunit. Experiments in these double point-mutated mice confirmed that α2 and α3 subunits were the most important subunits for diazepammediated antihyperalgesia also after systemic treatment. They also demonstrated that sedation and antihyperalgesia exhibit a similar dose-dependence, which stresses the problem of previous studies trying to distinguish antihyperalgesia from confounding sedation. Finally, they showed that the maximum levels of antihyperalgesia achievable with diazepam either in wild-type mice after spinal application or in α1(H101R) point-mutated mice after systemic application were very similar suggesting that pronociceptive effects arising from benzodiazepines at supraspinal sites are not of major relevance after systemic treatment.
The results obtained in GABA A receptor point-mutated mice provided the basis for the rational quest for benzodiazepine-site ligands with a better side-effect profile.
Several subtype-selective compounds have been identified and published in the recent years (Table 1) . To test whether such compounds would display antihyperalgesic efficacy after systemic treatment, we tested as a proof-of-principle experiment the α1-sparing (non-sedative) partial benzodiazepinesite agonist L-838,417, which is an antagonist at the benzodiazepine binding site of GABA A receptor α1 subunits and a partial agonist at α2, α3, and α5 [20] . L-838,417 not only reduced nociceptive withdrawal reflexes in behavioral studies in rats, but also decreased pain-related brain activity in functional magnetic resonance imaging (fMRI) experiments evoked by stimulation of an inflamed hindpaw [13] providing direct evidence that L-838,417 interfered with the sensory and emotional components of pain (and not just with nociceptive reflex activity). Similar antihyperalgesic effects were achieved in the mouse formalin test with SL651498, a full agonist at α2 and α3 subunits and a partial agonist at α1 and α5 subunits [21] , by our group [19] , and with NS11394, which displays a functional specificity profile of α5 > α3 > α2 > α1 [22] , by a different laboratory [23] (Table 2) . NS11394 displayed an antihyperalgesic efficacy in neuropathic pain models comparable to that achieved with gabapentin, a drug frequently used for the treatment of neuropathic pain in human patients. Data from this group also suggest that not only are rather high doses of benzodiazepines needed to yield sufficient antihyperalgesia (comparable to those required for sedation and significantly higher than anxiolytic doses) but also that a rather high intrinsic activity is necessary. Bretazenil, a non-selective Antihyperalgesic against inflammatory and neuropathic pain, no effect on acute pain (heat and mechanical stimulation), reduced hyperalgesia-related brain activity in fMRI experiments [13] SL651498 Reduced electrically evoked flexor reflexes, reduced flexor responses in the mouse formalin test [33] , [19] 
NS11394
No effect on acute pain in the hot plate test, reduced flexor responses in the formalin test, reduced capsaicin-induced flexor responses, increased weight bearing on inflamed paw, reduced neuropathic pain (allodynia) [23] agent with low intrinsic activity, was devoid of antihyperalgesic effects in different pain models despite of good anxiolytic activity [23] . Cases like that of bretazenil also demonstrate that the in vivo specificity of subtype-selective agents is determined not only by their subunit specificity but also by other factors including intrinsic activity, active metabolites, and pharmacokinetic properties such as on-set and duration of action. These factors often limit the comparability of data obtained with selective compounds or with genetically modified mice. Pharmacological and genetic evidence clearly indicates that a genuine antihyperalgesic effect of benzodiazepines exists after spinal as well as after systemic application-at least in mice and rats. The two pertinent questions at present are, can other unwanted effects besides sedation also be avoided with subtype-selective (or partial) agonists and does the concept of a benzodiazepine-mediated antihyperalgesia also work in humans. Both questions are at present difficult to answer. The latter one has to await the availability of subtype-selective agents suitable for clinical trials in humans. While L-838,417 possesses undesirable pharmacokinetics in man [24] , those of TPA023 and SL651498 appear favorable [25, 26] . It is, however, not yet clear whether these compounds would be suitable for human pain studies. Possible caveats include the rather low intrinsic activity of TPA023 [27] and remaining activity at α1 subunits of SL651498 [21] which might cause significant sedation when given in antihyperalgesic doses.
The question whether other side effects apart from sedation can be avoided with subtype-selective agents should in principle be easier to answer but is also not yet solved. Tolerance development (closely related to physical dependence), reinforcing properties (related to addiction), and memory impairment are probably the most relevant of such side-effects. There is some reason to assume that subtype-selective compounds should have a reduced risk for these side effects. Data obtained in α1(H101R) pointmutated mice indicate that potentiation of GABA A receptor α1 subunits underlies also the amnestic effects of benzodiazepines [17] . However, hippocampus-dependent learning involves also α5 GABA A receptors [28] , a finding which is supported by the positive cognitive effects of inverse agonists at α5 GABA A receptors [29] . Published evidence suggests that physical dependence does not occur with several α1-sparing agents (L-838,417, SL651498, and TPA023) [30] and at least in the case of L-838,417, tolerance against the antihyperalgesic effect was completely absent during a 9-day treatment period-in striking contrast to morphine, which had lost its analgesic activity already after 6 days [13] . However, besides subunit specificity the lower intrinsic activity of these compounds could also play a role [31] , leaving it open whether compounds with full intrinsic activity would retain this advantage. The potential reinforcing properties appear even more complex. High intrinsic activity at α1 GABA A receptors clearly promotes reinforcing effects of benzodiazepines, but compounds devoid of activity at α1 (such as L-838,417) still have some reinforcing potential [31] and other factors apart from subunit specificity and intrinsic activity such as a rapid onset of action in the CNS might contribute as well [32] .
In summary, recent evidence obtained either with genetically modified mice or with subtype-selective benzodiazepine site ligands indicates that benzodiazepines possess significant antihyperalgesic activity. With classical benzodiazepines, this antihyperalgesia requires a high receptor occupancy leading to strong sedation and other undesired effects which probably mask beneficial effects on pain and which preclude their therapeutic use as analgesics. Novel subtype-selective agents are in development which should not only lack undesired sedation but might also be devoid of other unwanted effects such as memory impairment, physical dependence, and addiction. They will likely possess anxiolytic and possibly muscle relaxant efficacy in addition to antihyperalgesic properties.
